每经大健康人物|康诺亚董事长陈博:从PD-1到自免药物 做更符合临床需求和发展趋势的创新药

每日经济新闻
21 Feb

从全球市场来看,自免疾病(自身免疫性疾病)领域已成为仅次于肿瘤疾病的第二大药物市场,也是全球重磅药物诞生的沃土。  根据赛诺菲发布的2024年年报,度普利尤单抗作为其核心产品,是公司业绩中最大的亮点。2024年度,度普利尤单抗的销售额高达130.72亿欧元(约合141.79亿美元),同比增长幅度达到23.1%。  去年9月,这一重磅药物迎来了全球第二款、国内首款同类产品。由康诺亚自主研发的1类新药...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10